Real-World Outcomes of Anti-CD38 Antibody–Treated, Including Triple-Class–Refractory, Patients With Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Blood Cancer J 2023 Dec 08;13(1)181, A Visram, A De La Torre, D White, J Su, E Masih-Khan, M Chu, V Jimenez-Zepeda, A McCurdy, R LeBlanc, K Song, H Mian, M Louzada, M Sebag, D Bergstrom, J Stakiw, A Reiman, R Kotb, M Aslam, C Venner, R Kaedbey, E Gul, D ReeceFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.